The Cancer Drug Caught in the FDA's Identity Crisis

No safety concerns were cited. Just questions about trial design and data interpretation that, by all accounts, hadn't been flagged before.

Replimune didn't give up. After a frustrating Type A meeting with the FDA in September 2025 that yielded no clear path forward, the company resubmitted its application in October with new analyses. The FDA accepted it on October 20, 2025, classifying it as a Class II complete response, and set the new decision date for April 10.

Musical Chairs at the FDA

Now, why does this decision feel like it carries extra weight? Because the FDA that rejected RP1 barely exists anymore.

CDER has burned through five directors in 2025 alone. Pazdur himself became CDER director in November 2025, only to retire by year's end. Peter Marks, the longtime CBER chief, resigned earlier in 2025 over vaccine policy disagreements with HHS leadership.

Vinay Prasad took over CBER in May 2025, got fired in July (partly over a dispute about a Duchenne muscular dystrophy drug), was reinstated ten days later, faced an internal probe for alleged toxic workplace behavior, and is now departing again at the end of April 2026. The agency has lost roughly 20% of its workforce, and recruiting replacements has been, to put it mildly, a challenge.

The person who blocked RP1's approval is gone. The person who reviewed it is gone. The person who replaced that person is leaving. It's like trying to get your landlord to fix your sink, except the building has had four different property managers since you filed the request.

Why Wall Street Is Watching

Replimune's stock tells the story of a company living and dying by this decision. Shares currently trade around $8.41 to $8.72, well below analyst targets that range from $10 to $19. The stock popped roughly 10.78% in early April on positive trial data buzz, but the company is still burning cash fast, with a net loss of $70.9 million in its most recent quarter and R&D spending of $53.1 million.

Analyst sentiment is split but cautiously hopeful. Piper Sandler has an Overweight rating with a $14 target. Wedbush is at $19 with an Outperform. Others are less convinced; Barclays had the stock as low as $3 back in July 2025, right after the rejection. Some analysts peg the approval odds at roughly 50-50, and a second rejection could force Replimune to pivot away from RP1 entirely.

The Bigger Question

RP1 is interesting on its own. An oncolytic virus (a virus engineered to selectively infect and destroy cancer cells) that works alongside nivolumab, with durable responses in patients who've run out of options? That's genuinely exciting science.

But the April 10 decision is about more than one drug. It's a litmus test for how the FDA operates under its current, depleted leadership. The agency rejected this drug under one regime. Can it objectively re-evaluate the same data under new management, especially when the political winds are swirling and experienced reviewers have walked out the door?

Industry watchers are nervous. The parade of departures has already disrupted reviews across rare diseases, gene therapies, and vaccines. Multiple drugs that likely would have been approved under prior leadership were rejected during the turmoil. Drugmakers don't know what to expect anymore, and uncertainty is the one thing biotech investors hate more than bad data.

What Happens Next

Three days. That's all that separates Replimune from either a historic approval or a potentially company-defining setback. If RP1 gets the green light, it validates the science of oncolytic immunotherapy in a way no previous drug has for this patient population. If it gets rejected again, serious questions follow about whether the FDA's institutional memory survived 2025 intact.

For Americans diagnosed with advanced melanoma each year who fail frontline treatment, the stakes aren't abstract. They're waiting for an option that the data suggests works meaningfully better than what's currently available. Whether they get it may depend less on the science and more on whether anyone's left at the FDA to sign off on it.

An AI Just Designed an Opioid Addiction Drug. No Human Chemist Required.

A computer just designed a new opioid addiction drug that doesn't touch opioid receptors at all. GATC Health's AI-generated candidate is heading into human trials, and it could signal a turning point for a field that's been stuck for decades.